



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/30	A1	(11) International Publication Number: WO 96/01124 (43) International Publication Date: 18 January 1996 (18.01.96)
<p>(21) International Application Number: PCT/SE95/00776</p> <p>(22) International Filing Date: 22 June 1995 (22.06.95)</p> <p>(30) Priority Data: 9402370-2 4 July 1994 (04.07.94) SE</p> <p>(71) Applicant (for all designated States except US): PHARMACIA AB [SE/SE]; S-171 97 Stockholm (SE).</p> <p>(72) Inventor; and (75) Inventor/Applicant (for US only): THIVOLET, Charles [FR/FR]; 37, cours Vitton, F-69006 Lyon (FR).</p> <p>(74) Agents: TANNERFELDT, Agneta et al.; Pharmacia AB, S-112 87 Stockholm (SE).</p>	<p>(81) Designated States: AU, CA, FI, JP, KR, MX, NO, NZ, RU, SK, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report.</i></p>	
(54) Title: USE OF IGF-I OR ANALOGUES THEREOF IN THE PREVENTION OF DIABETES		
<p>(57) Abstract</p> <p>The invention relates to the use of IGF-I or analogues thereof in the manufacture of a medicament useful in the prevention of diabetes, in delaying the clinical onset of diabetes and with protective effect against diabetes. It also relates to the use of IGF-I or analogues thereof in the manufacture of a medicament preventing beta cell destruction and the regulation of T cells in subjects which are at high risk of development of diabetes. The invention also relates to the method for protecting against diabetes, prevention of diabetes and delaying the clinical onset of diabetes by administration of IGF-I or analogues thereof.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

USE OF IGF-I OR ANALOGUES THEREOF IN THE PREVENTION OF DIABETES.

5 The present invention relates to the use of IGF-I or analogues thereof in the manufacture of a medicament useful in the prevention and delaying the clinical onset of diabetes and having a protective effect against diabetes.

The medicament is also useful in preventing beta cell destruction and regulating of T cells.

10

SUMMARY

Insulin like growth factor-1 (IGF-1) and insulin are structural homologues, and elicit insulin-like and growth-promoting effects. In addition, IGF-1 has important effects on thymocyte replication and function independently of those of insulin. To evaluate the effect of IGF-1 on the autoimmune process of beta cell destruction, permissive recipients were adoptively transferred with T cells from diabetic donors and 10µg of rhIGF-1 were administered subcutaneously twice daily. The recipients of 7×10^6 autoreactive T cells were followed for clinical manifestations of diabetes and examined for in situ lesions after three weeks of treatment. We observed that the administration of rhIGF-1 delays the clinical onset of the disease and reduces the final incidence of successful transfers since diabetes was observed in only 6/24 (25%) vs 12/21 (57%) in control mice. These effects were associated with a marked reduction of insulinitis. Mice treated with rhIGF-1 had a higher percentage of intact islets ($48.6 \pm 12\%$ vs $1.6 \pm 1.1\%$, $p=0.001$) and a lower percentage of infiltrated islets. However, some mice developed diabetes despite rhIGF-1 administration with severely infiltrated islets, indicating thus that committed T cells were still able to invade the islets and cause beta cell destruction. Three weeks after sub-lethal irradiation and T cell inoculation no difference was noticed in the percentages of CD4⁺ and CD8⁺ T cells in the spleen of experimental mice. To further elucidate whether rhIGF-1 could influence the homing of committed T cells, we adoptively transferred congenic NOD-N Thy-1,1 mice with T cells from diabetic NOD Thy-1,2 mice and monitored the numbers of Thy-1,2⁺ T cells present in lymphoid organs after three weeks of treatment. The administration of rhIGF-I was found to reduce significantly the percentage of Thy-1,2⁺ T cells in the spleen ($10.8 \pm 1.3\%$ vs $17.2 \pm 3.9\%$, $p=0.004$) in contrast to the thymus ($68.4 \pm 7.9\%$ vs 72.87 ± 6.2 , $p=0,306$). The findings that rhIGF-1 has protective effects and may

15
20
25
30
35

act prior to islet cell invasion opens new perspectives for future experiments and preventive strategies in human type 1 diabetes.

INTRODUCTION

5 The non-obese diabetes (NOD) mouse is an experimental model of spontaneous diabetes resembling human type 1 (insulin-dependent) diabetes, which results from the progressive islet invasion and beta cell destruction by autoreactive T cells (1,2). This spontaneous diabetes model offers a unique opportunity of studying the autoreactive T cells involved in the process of beta cell destruction
10 and of settling preventive strategies before clinical onset of the disease. The number of committed T cells in the spleens of diabetic animals (3) and the respective contribution of T cell subsets (4) can be evaluated in vivo during adoptive T cell transfer into non diabetic syngeneic animals.

15 Insulin like growth factor-1 (IGF-1), a 70-amino acid peptide structurally related to insulin, is normally considered to be a metabolic hormone which mediates many effects of growth hormone. Prophylactic insulin treatment of NOD mice during the prediabetic phase (5) as well as insulin treatment of the NOD recipients of autoreactive T cells during adult T cell transfer (6) have been
20 shown to prevent and/or delay the onset of diabetes and to reduce the severity of insulinitis. Similar results have been also obtained in BB rats (7,8), which as another animal model of spontaneous autoimmune diabetes. Since insulin is a major antigenic component of the beta cells, it was not clear from these experiments whether insulin protective effects were explained by an antigen-
25 specific unresponsiveness of the immune system, by a direct suppressive effect on T cell function, or by a direct effect on the beta cells.

The present study was undertaken to examine whether rhIGF-1 may have protective effects in the autoimmune diabetes of NOD mice using adoptive T cell transfer experiments.

30

THE INVENTION

The invention relates to the use of IGF-I or analogues thereof in the manufacture of a medicament useful in the prevention of diabetes and in delaying the clinical onset of diabetes.

35 IGF-I has also shown to have a protective effect against diabetes, is preventing beta cell destruction in subjects which are at high risk of development of

diabetes and in the regulation of T cells in subjects which are at high risk of developing diabetes.

5 The invention relates to a method for treating patients having the above mentioned problems by administration of IGF-I or analogues thereof.

Possible daily dosages of IGF-I are 20 to 500 µg/kg or preferably 20 to 250 µg/kg or more preferably 100 to 200 µg/kg.

10 5 figures are illustrating the results of the experiments.

Figure 1 Cumulative incidence of diabetes in four independent in mice

Figure 2 Severity of insulinitis and destructive lesions

Figure 3 Immunodetection of Thy-1,2⁺ T cells in the islets of congenic NOD-N Thy-1,1 mice

15 Figure 4 FACS analysis of Thy-1,2⁺ T cells within the spleen of a congenic NOD-N Thy-1,1 mouse

Figure 5 FACS analysis of Thy-1,2⁺ T cells within the thymus of a congenic NOD-N Thy-1,1 mouse

20

MICE AND METHODS

1. Mice

NOD mice were bred under standard conditions in our own facilities. The
25 incidence of spontaneous diabetes in our colony reached 80 % in females by 30 weeks whereas diabetes occurred in only 20 % of males in the same period. Congenic NOD-N Thy-1,1 mice initiated from a cross between NOD/Lt and a diabetes resistant strain NON/Lt were obtained from Ed. Leiter, Bar Harbor Michigan (10). Diagnosis of diabetes was characterized by polydipsia, weight
30 loss, glycosuria (Urine chemstrips, Ames-Bayer, Germany) and persistent hyperglycemia (Blood glucose chemstrips, Lifescan USA). Diabetic NOD females served as donors of autoreactive T cells. Four different experiments of adoptive cell transfer of diabetes were performed using 46 male recipients and 22 diabetic females.

35

2. Cells

Splenocytes from diabetic mice were isolated in Hanks' balanced salt solution (HBSS) and enriched T cell populations were obtained by filtration through nylon wool columns eluting 20 to 25 % of the initial cell preparation. More than 90 % of the final cell suspension was from the Thy 1,2⁺ phenotype during flow cytometry analysis. After numeration and viability evaluation, $7 \cdot 10^6$ T cells were i.v. injected into 8 to 10 week-old irradiated NOD males (750 rads) according to the method of Wicker et al (3).

3. Protocol of treatment

Fast-acting insulin stock solution (Actrapid HM, Novo Nordisk Copenhagen, Denmark) was prepared with a 9 % NaCl solution at a final concentration of 5 U/ml. Recombinant human IGF-1 (rhIGF-1) was obtained from Dr Anna Skottner (Kabi Pharmacia, Stockholm, Sweden) and aliquoted to a final concentration of 100 µg/ml. The day following adoptive cell transfer, mice were s.c. injected twice daily 100µl containing either 0.5 U of insulin, 10µg of rhIGF-1 or saline. Recipient mice received approximately 30 U/kg/day of insulin and 0.6 mg/kg/day of rhIGF-1 over a period of three weeks. The onset of glycosuria was monitored daily starting at day 15.

4. Histologic procedures

All mice were killed by cervical dislocation. Pancreatic glands were excised and processed for conventional histological studies after fixation in Bouin's alcoholic solution. Five µm sections were stained with haematoxylin-eosin, as described previously (6). The severity of insulinitis was scored for at least 25 islets for each specimen, wherein islet cells which had no visible sign of inflammation were scored 0, islets which had lymphocytes at the periphery i.e. peri-insulinitis were scored 1, islets which were mildly infiltrated (<40 %) were scored 2, islets which were completely infiltrated were scored 3. The percentages of islets of each category were compared between the different groups of mice. The number of beta cells was determined by immunohistochemistry on fixed sections, using an anti-human insulin monoclonal antibody (Novoclone HUI 018, NovoBiolabs, Bagsvaerd Denmark) diluted 1:50 and an anti-human proinsulin monoclonal antibody (Novoclone HPUI). An FITC rabbit anti-mouse IgG (Dako, Burlingame USA) dilution 1:50 was used as a conjugate.

5. T cell subset analysis

After 3 weeks of treatment, spleens from experimental animals were subjected to T cell subset analysis using an anti-Thy1,2 (clone 30H12), anti-L3T4 (clone GK 1,5) and anti-Lyt2 (clone 53-67) rat monoclonal antibodies and a FITC-
5 conjugated anti-rat IgG kappa antibody (MARK-1, Biosys, Compiègne France). To evaluate the influence of rhIGF-1 treatment upon the homing of autoreactive T cells, the percentages of Thy-1,2⁺ T cells injected into NOD-N Thy-1,1 recipients were determined in lymphoid organs by FACS analysis as well as in islet infiltrates by immunohistochemical procedures on pancreatic sections.

10

6. mRNA studies

In order to study the number of mRNA transcripts for insulin in the pancreas of experimental mice, the total RNA content was precipitated in 4M guanidine thiocyanate and then in 7.5M guanidinium hydrochloride (Sigma, St-Louis MO)
15 solutions and extracted in chloroform-butanol (100/24, vol/vol). Four different concentrations of ARN ranging from 2.5 to 20µg were hybridized on nylon membranes with P32-labelled cDNA rat proinsulin probes (obtained from C. Dagorn, Marseille France). Films were analyzed by densitometric scanning after
20 24 hrs of exposure period.

7. Statistical analysis

The effects of treatment on diabetes transfer were analyzed using the Wilcoxon test. Scores of insulinitis were compared using Student's test for unpaired
25 samples.

RESULTS

Effects of rhIGF-1 treatment on T cell transfer of diabetes

30 In order to evaluate the effects of hormonal treatment on the diabetes transfer capacity of autoreactive T cells, we initiated the injection protocol on the day following the adoptive T cell transfer and continued for an overall period of three weeks. The effects of rhIGF-1 on blood glucose levels were determined in a separate experiment. Glucose levels dropped significantly (81.5 ± 0.7 mg/dl) 30
35 minutes after a single s.c. injection of 10 µg of rhIGF-1, and after 2 hours increased above normal values (181 ± 19.8 mg/dl) before returning to baseline. During the treatment period, the effects of rhIGF-1 on body weight were

monitored every two days. rhlGF-1 was able to maintain the body weight of recipient mice, in contrast to saline and/or insulin injections, (Table I). However, these effects were closely dependent on the presence of clinical diabetes.

5 The occurrence of clinical diabetes was determined in rhlGF-1 treated mice and compared with saline and insulin treated groups. Diabetes was detected in only 6 out of 24 (25 %) mice treated with rhlGF-1, in contrast to 12/21 (67 %) in control mice and 6/14 (42.8 %) mice treated with insulin. Insulin like growth factor-1 was associated with a significant reduction in diabetes incidence
10 (p=0.016) as shown in Figure 1 with a significant delay in the clinical onset of the disease. In addition, insulin-treated mice (p=0.01) also had a significantly lower incidence rate of diabetes than control mice. The treatment of diabetic NOD females with rhlGF-1 twice daily over a period of 7 days prior to transfer, failed to modify the number and degree of activation of the autoreactive T cells
15 contained in the spleens of experimental animals and the diabetes incidence curves were found to be the same after one month.

Histological studies

20 The severity of insulinitis was quantified and a comparison was made between the different experimental groups of animals. As shown in figure 2, when compared to sham-injected mice, mice that had been treated with rhlGF-1 were found to have a higher percentage of normal (e.g. non infiltrated) islets ($48.6 \pm 12.1\%$ vs $1.62 \pm 1.1\%$, p=0.001) and a lower percentage of islets with mild ($15.8 \pm 5.1\%$ vs $31.5 \pm 2.8\%$, p=0.016) or severe insulinitis ($22.43 \pm 8.8\%$ vs $59.82 \pm 6.5\%$,
25 p=0.003). However, no significant difference was found in the percentage of peri-insulinitis ($7 \pm 4.5\%$ vs $13.1 \pm 5.8\%$, p=0.424).

Interestingly, islets from 4/12 mice which received rhlGF-1 were free from lymphocytic infiltration in contrast to 0/11 mice in the control group. Thus, rhlGF-1 reduced both the intensity and the prevalence of insulinitis.

30

Effects of rhlGF-1 on insulin synthesis

Although the number of intact beta cells was higher in rhlGF-1 treated animals, no difference was noticed in the intensity of the fluorescent pattern of the remaining beta cell at the end of the treatment period in mice that had been
35 treated with either rhlGF-1 or with saline. In addition, the levels of mRNA transcripts for proinsulin in non diabetic mice during dot blot analysis were comparable in both situations, thus indicating that at the doses used in the

present experiments rhIGF-1 does not modulate significantly the rate of insulin synthesis.

Effects of rhIGF-1 on T cell homing

5 Because insulinitis is a T cell phenomenon, we suspected that rhIGF-1 might interfere with the kinetics of the migration of committed T cells to the pancreas. Congenic NOD-N Thy-1,1 males were adoptively transferred with T cells from diabetic NOD Thy-1,2 animals. Diabetes occurred in 3/6 mice that had been treated with saline and 0/6 mice that had been treated with rhIGF-1, after 3
10 weeks of treatment. This apparent protective effect was also associated with a decrease in the severity of islet cell infiltrates, which were composed exclusively by T cells from donor origin with no recruitment of host T cells as shown in figure 3. When analyzed in individual mice, the number of Thy-1,2⁺ T cells was found to be significantly lower in the spleen of treated mice with rhIGF-1 in
15 comparison with control mice (Table III and figure 4), although no significant difference was noticed within the thymus (figure 5).

DISCUSSION

The adoptive T cell transfer model in the NOD mouse explores in vivo the
20 capacity of autoreactive T cells to cause destructive lesions and ultimately type I diabetes. In the present study, we have demonstrated that rhIGF-1 is able to reduce the capacity of large amounts of committed T cells from invading NOD islets during adoptive T cell transfer. These results reproduce those previously obtained with human insulin (6). However, the present experiments clearly
25 demonstrate that rhIGF-1 is more potent than insulin in preventing diabetes transfer at concentrations 10 times less to those giving comparable metabolic effects in diabetic rats (11). Despite the injection of high numbers of autoreactive T cells, rhIGF-1 was found to delay the time of onset and to reduce the maximal frequency of clinical diabetes. In addition, strong histological evidence indicate
30 that rhIGF-1 prevents massive islet cell invasion and fully protects one third of the treated mice.

There are distinct classes of mechanisms which may be responsible for the prevention of beta cell destruction by IGF-1. First, the effect may be on the beta
35 cells. Specific receptors on the surface of beta cells as well as local production of this growth factor have been identified (12). Recently, an enhanced IGF-1 gene expression has been shown in regenerating rat pancreas after partial

pancreatectomy (13,14). However, we were unable to find any difference in the number of insulin and/or proinsulin positive cells within the islets. However, the conservation of insulin-producing beta cells was associated with a marked reduction in islet infiltration, suggesting that the contribution of beta cell
5 regeneration was not essential. Insulin-like growth factor 1 may also on the other hand, be considered as a regulator of insulin release in view of its inhibitory effects at physiological concentrations (15). Although the hypothesis of beta cell rest formulated during early and prolonged insulin therapy (5) might also be evacuated, no difference was noticed in the intensity of insulin
10 staining of the beta cells and in the number of mRNA transcripts for proinsulin.

The observation of pancreatic glands free from insulinitis under rhIGF-1 treatment, suggests another mechanism that occurs prior the late activation process of infiltrating T cells by eliminating or inactivating the functional
15 properties of autoreactive T cells necessary for beta cell destruction. Recombinant hIGF-1 may exert these effects directly on lymphoid cells, since in vitro suppression of T cell response to concanavalin A or allogeneic stimulation can be achieved in a dose dependent manner (16). Many actions of growth-hormone on the immune system may be mediated by IGF-1 which is also
20 produced by peripheral leukocytes (17). Recent observations suggest that activated T lymphocytes possess receptors for IGF-1 (18-20). In addition, several reports indicate that IGF-1 may influence thymic epithelial cell function in vitro (21) and induce thymocyte replication and differentiation in streptozocin induced diabetic rats (22). Mice which receive 4 mg/kg per day of rhIGF-1 were
25 found to have an increased spleen and thymus weight, due to an increase in the number of lymphocytes in these organs, preferentially T cells from the CD4 phenotype (22). We did not observe any difference in the number of T cells in the lymphoid organs and in the relative contribution of T cell subsets within the spleen, probably because of lower doses of rhIGF-1 used in the present study.
30 Moreover, treatment of diabetic females with rhIGF-1 failed to reduce the capacity of spleen cells to transfer the disease, suggesting that the number and degree of activation of autoreactive T cells were not modified.

The effect may be also on the mechanisms of T cell trafficking into the islets
35 during the 10 days period after T cell inoculation that precedes islet cell invasion (23). T cell homing to the pancreas and endothelial-lymphocyte interactions might be regulatory events. Reconstitution of the thymus of

irradiated congenic NOD-N Thy-1,1 recipients with Thy-1,2⁺ T cells was not influenced by rhIGF-1. The significant reduction in the number of T cells from donor origin noticed within the spleen may contribute to the protective effects of IGF-1 during adoptive T cell transfer. A reduction in the number but not in the degree of activation of autoreactive T cells may explain why rhIGF-1 treated mice are not fully protected and why diabetes can still occur.

From the present observations, rhIGF-1 should be considered as an important regulator of autoreactive T cells through autocrine but also endocrine actions, which might have clinical consequences during the prediabetic phase in human type 1 Diabetes.

LEGENDS OF FIGURES

Figure 1: Cumulative incidence of diabetes in four independent experiments following adoptive T cell transfer in 24 mice injected twice daily with 10 μ rhIGF-1 (open circles) and 21 control mice injected with saline (closed circles).

Figure 2: Severity of insulinitis and destructive lesions of recipient mice according to treatment with saline (dark columns) or rhIGF-1 (open columns). Results are mean percentages \pm SE from 24 individual mice from two independent experiments.

*: $p < 0.05$, **: $p < 0.01$.

Figure 3: Immunodetection of Thy-1,2⁺ T cells in the islets of congenic NOD-N Thy-1,1 mice three weeks after adoptive cell transfer of diabetes using 7×10^6 T cells from NOD Thy-1,2 diabetic donors. Panel A illustrates a severe insulinitis in a control mouse. Panel B represents a peri-insulinitis in a mouse treated with rhIGF-1

Figure 4: FACS analysis of Thy-1,2⁺ T cells within the spleen of a congenic NOD-N Thy-1,1 mouse, three weeks after sub-lethal irradiation and inoculation of Thy-1,2⁺ T cells from diabetic donors. Panel A represents the results in a control NOD-N Thy-1,1 mouse. Insulin like growth factor-1 significantly reduced the number of Thy-1,2⁺ in the spleen (Panel B) in comparison to saline (Panel C).

Figure 5: FACS analysis of Thy-1,2⁺ T cells within the thymus of a congenic NOD-N Thy-1,1 mouse, three weeks after sub-lethal irradiation and inoculation of Thy-1,2⁺ T cells from diabetic donors. Panel A represents the results in a control NOD-N Thy-1,1 mouse. The effects of rhIGF-1 upon the reconstitution of the thymus after T cell transfer are shown in Panel B and are compared to saline injected mouse (Panel C).

5 **TABLE I.** Variation in the body weight of experimental mice injected with IGF-1, insulin or saline over a period of 3 weeks. Each value represents the mean \pm SE (n).

Treatment	Weight (g)		p value
	Day 1	Day 21	
Saline	30.13 \pm 0.38 (n=22)	28.71 \pm 0.49 (n=21)	0.027
15 Insulin	29.61 \pm 0.39 (n=17)	28.13 \pm 0.44 (n=14)	0.018
rhIGF-1	29.63 \pm 0.34 (n=24)	29.68 \pm 0.52 (n=24)	0.946

20

5 **TABLE II.** Flow cytometry analysis of Thy-1,2⁺, L3T4⁺ and Lyt-2⁺ T cells in the spleens of experimental mice treated with rhIGF-1 or saline. Results are mean \pm SE of individual analysis performed on 12 different mice from each group.

Treatment	Percentage of cell population		
	Thy-1,2 ⁺	L3T4 ⁺	Lyt-2 ⁺
Saline	14.78 \pm 1.05	14.98 \pm 0.76	6.63 \pm 0.39
15 rhIGF-1	21.95 \pm 1.87	12.72 \pm .148	5.19 \pm 0.62
p value	0.266	0.258	0.104

20

5 **TABLE III:** Percentages of Thy-1,2⁺ T cells in the spleen and thymus of experimental congenic NOD-N Thy-1,1 mice three weeks after sub-lethal irradiation and adoptive transfer of 7x10⁶ Thy-1,2⁺ from diabetic donors. Results are the mean±SE of 12 individuals mice.

	Thymocytes		Splenocytes		
	n(x10 ⁶)	% of Thy-1,2 ⁺ T cells	n(x10 ⁶)	% of Thy-1,2 ⁺ TCells	
10					
15	rhIGF-1 (n=6)	36.8±2.3	68.43±3.2	60±2.4	10.86±0.5
	saline (n=6)	35.1±1.5	72.88±2.5	56±4.8	17.19±1.6
20	p value	0.559	0.306	0.102	0.004

25

REFERENCES

1. Castano, L., Eisenbarth, G.S.: Type 1 diabetes: a chronic autoimmune disease of human, mouse and rat. *Ann. Rev. Immunol* 1990; 8:647-679.
- 30 2. Makino, S., Kunimoto, K., Mureoka, Y., Mizushima, Y., Katagiri, X., Tochino, Y.: Breeding of a non-obese diabetic strain of mice. *Exp. Anim.* 1980;29:1-13.
- 35 3. Wicker, L.S., Miller, B.J., Mullen Y.: Transfer of autoimmune diabetes mellitus with splenocytes from non-obese diabetic (NOD) mice. *Diabetes* 1986;35:855-860.

4. Thivolet, D.H., Bendelac, A., Bedossa, P., Bach, J.F., Carnaud, C. : CD8⁺ T-cell homing to the pancreas in the non-obese diabetic mouse is CD4⁺ T-cell-dependent. *J. Immunol.* 1991;146:85-88.
- 5 5. Atkinson, M.A., MacLaren, N.K., Luchetta, R.: Insulinitis and diabetes in NOD mice reduced by prophylactic insulin therapy. *Diabetes* 1990;39:933-937.
6. Thivolet, C.H., Goillot, E., Bedossa, P., Durand, A., Bonnard, M., Orgiazzi, J. : Insulin prevents adoptive cell transfer of diabetes in the autoimmune non-obese diabetic mouse. *Diabetologia* 1991;34:314-319.
10
7. Like, A.A. : Insulin injections prevent diabetes (DB) in biobreeding/Worcester (BB/Wor) rats. *Diabetes* 1986;35 (suppl. 1):74.
- 15 8. Bertrand, S., De Paepe, M., Vigeant, C., Yale, J.F.: Prevention of adoptive transfer in BB rats by prophylactic insulin treatment. *Diabetes* 1992;41: 1273-77.
9. Binz, K., Joller, P., Froesch, P., Binz, H., Zapf, J., Froesch, E.R. : Repopulation of the atrophied thymus in diabetic rats by insulin like growth factor 1. *Proc. Natl. Acad. Sci. USA* 1990;87:3690-3694.
20
10. Prochazka, M., Serreze, D.V., Worthen, S.M., Leiter, E.H. : Genetic control of diabetogenesis in NOD/Lt Mice: Development and analysis of congenic stocks, *Diabetes* 1989;38: 1446-1455.
25
11. Jacob, R.M., Sherwin, R.S., Bowen, L., Fryberg, D., Fagin, K.D., Tamborlane, W.V., Shulman, G.I. : Metabolic effects of IGF-1 and insulin in spontaneously diabetic BB/w rats. *Am. J. Physiol.* 1991;260:E262-E268.
- 30 12. Van Schravendijk, C.F.H., Foriers, A., Van den Brande, J.L., Pipeleers, D.G. : Evidence for the presence of Type 1 insulin like growth factor receptors on rat pancreatic A and B cells, *Endocrinology* 1987;121:1784-1788.
13. Swenne, I., Pancreatic beta-cell growth and diabetes-mellitus. *Diabetologia*
35 1992;35: 193-201.

14. Smith, F.E., Rosen K.M., Villa-Komaroff, L., Weir, G.C., Bonner-Weir, S.,
Enhanced insulin-like growth factor 1 gene expression in regenerating rat
pancreas, Proc. Natl. Acad. Sci. USA 1991, 88:6152-6156.
- 5 15. Guler, H.P., Schmid, C., Zapf, J., Froesch, E.R. : Effects of recombinant insulin-
like growth factor 1 on insulin secretion and renal function in normal human
subjects, Proc. Natl. Acad. Sci. USA 1989;86:2868-2872.
- 10 16. Hunt, U., Eardley, D.D. : Suppressive effects of insulin and insulin like growth
factor 1 (IGF-1) on immune responses. J. Immunol. 1986;136:3994-3999.
17. Baxter, J.B., Blalock, J.E., Weigent, D.A. : Characterization of Immunoreactive
Insulin-Like Growth Factor-1 from Leukocytes and Its Regulation by Growth
Hormone. Endocrinology 1991;129: 1727-1734.
- 15 18. Tapson, V.F., Boni Schnetzler, M., Pilch, P.F., Center, D.M., Berman, J.S. :
Structural and functional characterization of the human T-lymphocyte receptor for
insulin-like growth-1 in vitro. J. Clin. Invest. 1988;82:950-957.
- 20 19. Stuart, C.A., Meehan R.T., Neale, L.S., Cintron, N.M., Furlanetto, R.W. : Insulin-
like growth factor binds selectively to human peripheral blood monocytes and B-
lymphocytes. J. Clin. Endocrinol. Metabol. 1991; 72:1117-1122.
20. Kojima, R., Willems, M., Dehaas, C.J.C., Rijkers, G.T., Schuurmans, A.L.G.,
25 Vanbuuloffers, S.C. : Expression of type-1 insulin-like growth factor receptors on
human peripheral blood mononuclear cells, Endocrinology 1992; 131: 2244-2250.
21. Timsit, J., Savino, W., Safieh, B., Chanson, P., Gagnerault, M.C., Bach, J.G.,
Dardenne, M. : Growth hormone and insulin-like factor 1 stimulate hormonal
function and proliferation of thymic epithelial cells, J. Clin. Endocrinol. Metab.
30 1992;75: 183-188.
22. Clark, R., Strasse, J., McCabe, S., Rabbins, K., Jardieu, P. : Insulin-like growth
factor-1 stimulation of lymphopoiesis, J. Clin. Invest. 1993;92:540-548.
- 35 23. Bedossa, P., Bendelac, M., Bach, J.F., Carnaud, C., Syngeneic T cell transfer of
diabetes into NOD newborn mice: in situ studies of the autoimmune steps leading
to insulin producing cell destruction, Eur.J. Immunol. 1989;19:1947-1951.

CLAIMS

5

1. Use of IGF-I or analogues thereof in the manufacture of a medicament useful in the prevention of diabetes.

10

2. Use of IGF-I or analogues thereof in the manufacture of a medicament useful in delaying the clinical onset of diabetes.

15

3. Use of IGF-I or analogues thereof in the manufacture of a medicament having a protective effect against diabetes.

20

4. Use of IGF-I or analogues thereof in the manufacture of a medicament preventing beta cell destruction in subjects that are at high risk of developing diabetes.

5. Use of IGF-I or analogues thereof in the manufacture of a medicament for regulating T cells in subjects at high risk of developing diabetes.

25

6. Method for preventing diabetes by administration of IGF-I or analogues thereof.

7. Method for delaying the clinical onset of diabetes by administration of IGF-I or analogues thereof.

30

8. Method for protecting against diabetes by administration of IGF-I or analogues thereof.

9. Method for preventing beta cell destruction in subjects which are at high risk of developing diabetes by administration of IGF-I or analogues thereof.

35

10. Method for regulating of T cells in subjects which are at high risk of developing diabetes by administration of IGF-I or analogues thereof.

1/5




Fig. 1

2/5




Fig. 2

3/5




Fig. 3




Fig. 4




Fig. 5

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 95/00776

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61K 38/30

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MEDLINE, CA, WPI

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0331630 A1 (CIBA-GEIGY AG), 6 Sept 1989 (06.09.89) --	1-5
X	Diabetes, Volume 40, April 1991, Luciano Rossetti et al, "Metabolic Effects of IGF-I in Diabetic Rats" page 444 - page 448 --	1-5
X	WO 9323071 A1 (KABI PHARMACIA AB), 25 November 1993 (25.11.93) --	1-5
X	Trends in endocrinology and metabolism, 1990, E. Rudolf Froesch et al: "Therapeutic Potential of Insulinlike Growth Factor I", se page 254 --	1-5

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

26 October 1995

Date of mailing of the international search report

02 -11- 1995

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Carolina Gómez Lagerlöf
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 95/00776

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 6-10
because they relate to subject matter not required to be searched by this Authority, namely:
See PCT Rule 39.1.(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

02/10/95

International application No.

PCT/SE 95/00776

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A1- 0331630	06/09/89	SE-T3- 0331630 AU-A- 2899989 CA-A- 1336815 DE-U- 6890520 DK-B- 169233 IL-A- 104777 JP-A- 1233227 US-A- 4988675	10/08/89 29/08/95 15/04/93 19/09/94 07/10/94 19/09/89 29/01/91
WO-A1- 9323071	25/11/93	NONE	